Weekly Recap: sunRIZE Phase 3 failure and No revenue, FY2026 loss
Rezolute, Inc. (NASDAQ:RZLT) said its Phase 3 sunRIZE in congenital hyperinsulinism missed the primary endpoint but submitted extra analyses and awaits FDA feedback, while ENDO 2026 data showed promising response in tumor-related hypoglycemia; HC Wainwright kept a Buy and raised its $10 target desp…